PLIVA Opens New Oral Solid Forms Facility
Zagreb, 18 October 2013 - The new Oral Solid Forms Facility was officially opened at PLIVA on 18 October 2013 in the presence of Zoran Milanović, Prime Minister of Croatia, Branko Grčić, Deputy Prime Minister and Minister of Regional Development and EU Funds, and Ivan Vrdoljak, Minister of Economy.
The new facility at the production site in Zagreb will considerably increase PLIVA's production capacities for tablets and capsules and directly increase exports as the majority of these products are intended for international markets. This more than USD 100 million worth investment at PLIVA's manufacturing site in Zagreb also covers the transfer of the existing pilot plant for tablets to the new facility and a considerable increase of production capacities for sterile forms. The basic features of this facility are innovative technologies and cutting-edge and state-of-the-art equipment. Furthermore, these production processes are among the most demanding in the pharmaceutical industry and must comply with special environmental monitoring requirements.
"This year has been especially important for us - we are about to complete one of the largest investment cycles in the company's history. I am glad that Teva is today one of the biggest private investors in Croatia and that its investments in the production facilities in Zagreb and Savski Marof total more than USD 200 million. In addition to production and exports growth, this investment is important because it opens new jobs. Furthermore, every new job at PLIVA multiplies a number of new jobs at the companies - suppliers participating in PLIVA's production chain", emphasised Tihomir Orešković, President of PLIVA's Management Board, and added: "I would like to use this opportunity and say that we are glad that an additional USD 20 million investment in sterile forms has been also approved."
When presenting the new production facility Miran Denac, Ph.D., a Member of PLIVA's Management Board and Director of Operations Croatia, said: "The investments in the facility at the Zagreb site amount to about USD 100 million and this facility has the cutting edge and state-of-the-art equipment. Highly qualified employees have been trained in operating new production lines, and following the gradual exploitation of production capacities, new jobs will be opened in this production facility. I would like to thank the project team for their expertise, good organisation, and innovation when needed most, and for having completed the project within timelines and our investment plan."
The eminent guests, accompanied by their hosts, made a tour of the new oral solid forms facility that raises PLIVA's and Teva's annual capacity by 2 billion tablets or more than 25%. Medicinal products manufactured in the new production facility are mainly intended for demanding EU and USA markets, and commercial production will start as soon as the facility is approved by the FDA and other regulatory agencies.
For additional information contact:
Tamara Sušanj Šulentić
PLIVA HRVATSKA d.o.o.
Tel: +385 1 3724 852
Fax: +385 1 3724 358